Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | FHIT | P49789 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12495027 | 0.82 | ALDH1A1 (0.50) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL11283109 | 0.81 | KMT2A (0.56) | ALDH1A1HTTKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3983956 | 0.79 | BCAT1 (0.53) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL15440476 | 0.74 | CYP1A2 (0.60) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL10642406 | 0.71 | HTT (0.58) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL924805 | 0.70 | ALDH1A1 (0.62) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL25078677 | 0.69 | ALDH1A1 (0.61) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL15422556 | 0.69 | BCAT1 (1.00) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL20968335 | 0.68 | KMT2A (0.47) | BCAT1LMNAALDH1A1HTTKMT2A | |
| SCHEMBL14081369 | 0.68 | KMT2A (0.47) | BCAT1LMNAALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2018-02-01 | — | — | US | disclosed |
| US-9815795-B2 | Pyridazinone and pyridone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2017-11-14 | — | — | US | disclosed |
| US-20160244414-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2016-08-25 | — | — | US | disclosed |
| US-9371290-B2 | Pyridazinone compounds | BIOTIE THERAPIES CORPORATION (FI) | 2016-06-21 | — | — | US | disclosed |
| US-20140024648-A1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | BIOTIE THERAPIES CORPORATION (FI) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244414-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | BCAT1 3234/4885LMNA 2000/4885ALDH1A1 259/4885 |
| US-20140024648-A1 | NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | BCAT1 3500/4885LMNA 2426/4885ALDH1A1 245/4885 |
| US-20180029995-A1 | PYRIDAZINONE AND PYRIDONE COMPOUNDS | XDH, PNPO, PDXK | BCAT1 3234/4885LMNA 2000/4885ALDH1A1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.